Post–Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 어수택 | - |
dc.contributor.author | Hee-Young Yoon | - |
dc.date.accessioned | 2022-11-29T06:41:43Z | - |
dc.date.available | 2022-11-29T06:41:43Z | - |
dc.date.created | 2022-11-28 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 1738-3536 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21876 | - |
dc.description.abstract | Coronavirus disease 2019 (COVID-19) has become a major health burden worldwide, with over 450 million confirmed cases and 6 million deaths. Although the acute phase of COVID-19 management has been established, there is still a long way to go to evaluate the long-term clinical course or manage complications due to the relatively short outbreak of the virus. Pulmonary fibrosis is one of the most common respiratory complications associated with COVID-19. Scarring throughout the lungs after viral or bacterial pulmonary infection have been commonly observed, but the prevalence of post– COVID-19 pulmonary fibrosis is rapidly increasing. However, there is limited information available about post–COVID-19 pulmonary fibrosis, and there is also a lack of consensus on what condition should be defined as post–COVID-19 pulmonary fibrosis. During a relatively short follow-up period of approximately 1 year, lesions considered related to pulmonary fibrosis often showed gradual improvement; therefore, it is questionable at what time point fibrosis should be evaluated. In this review, we investigated the epidemiology, risk factors, pathogenesis, and management of post–COVID-19 pulmonary fibrosis. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한결핵및호흡기학회 | - |
dc.title | Post–Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention | - |
dc.title.alternative | Post–Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 어수택 | - |
dc.identifier.doi | 10.4046/trd.2022.0053 | - |
dc.identifier.scopusid | 2-s2.0-85140247619 | - |
dc.identifier.bibliographicCitation | Tuberculosis and Respiratory Diseases, v.85, no.4, pp.320 - 331 | - |
dc.relation.isPartOf | Tuberculosis and Respiratory Diseases | - |
dc.citation.title | Tuberculosis and Respiratory Diseases | - |
dc.citation.volume | 85 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 320 | - |
dc.citation.endPage | 331 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002883825 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Coronavirus Disease 2019 | - |
dc.subject.keywordAuthor | Pulmonary Fibrosis | - |
dc.subject.keywordAuthor | Complications | - |
dc.subject.keywordAuthor | Incidence | - |
dc.subject.keywordAuthor | Pathogenesis | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Treatment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.